IceCure enrols initial patients for ProSense cryoablation trial in US
IceCure Medical has enrolled its first two patients in the US for the ChoICE study, evaluating its ProSense cryoablation system for low-risk breast cancer treatment. The trial aims to recruit 400 patients across 30 centers. ProSense is FDA-cleared for treating small, low-risk breast tumors in patients aged 70+ who are ineligible for surgery. The company aims to gather real-world evidence and expand clinical adoption.
How this was made

The 30-second read
Why it matters
The enrollment of the first patients is a primary disclosure that could lift the stock as investors view it as a de‑risking milestone.
Market read
First‑patient enrollment in a cleared breast‑cancer device trial is a fresh catalyst for IceCure Medical (ICU).
What to watch
Reimbursement policies and competition from alternative ablation technologies could limit adoption.
Background
IceCure Medical is expanding its ProSense cryoablation system into a post‑marketing US trial after FDA clearance.
Market effects
May increase interest in minimally invasive breast‑cancer devices and related oncology tech.
Supports US biotech activity and trial site expansion.
Limited to niche oncology device market.
Counterpoint
Early enrollment does not guarantee successful outcomes; later trial phases could face setbacks.
Key entities
- companyIceCure Medical
Developer of the ProSense cryoablation system.
- clinical_siteWest Cancer Center & Research Institute
First US site enrolling a patient.
- clinical_siteAdventist Health Glendale
Second US site enrolling a patient.

